Efficacy and Safety of Adalimumab and Infliximab for Noninfectious Uveitis

Noninfectious uveitis (NIU) is an immune-mediated response commonly associated with systemic diseases (e.g., Behçet’s disease) and nonsystemic inflammatory conditions (e.g., birdshot choroidopathy), or it may be idiopathic. Although corticosteroids are a mainstay of NIU treatment, steroid-sparing therapies such as anti–tumor necrosis factor α biologics and systemic immunomodulators allow for steroid tapering and mitigation of long-term side effects.